State urges centre to step in as medicine MRP far exceeds purchase cost
According to an official statement from Karnataka’s Home Ministry, the FDA’s recent inspection found that certain oncology medicines, antibiotics and medical consumables are priced at more than 40‑times their actual acquisition cost.
For example, the landing cost of Gufipol supplied by Criticare is Rs 86, while the MRP stands at Rs 4,528 – a 52.6‑fold increase. Similar gaps were recorded for Guficylin‑50 injection (Rs 160 landing cost vs Rs 7,110 MRP) and Turlitis (Rs 118 vs Rs 4,416 MRP). The disparity extends to equipment such as adult nebuliser masks (Rs 44.50 versus Rs 950 MRP) and IV sets (Rs 14.75 versus Rs 295 MRP).
Health Minister U.T. Khadar wrote to the Union Health Minister on September 23, requesting concrete steps to curb inflated billing.